PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



cvfile 0023229.pdf


Preview of PDF document cvfile-0023229.pdf

Page 1 2 3 4 5 6

Text preview


- An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and
vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior
trastuzumab treatment, sponsored by Boehringer Ingelheim, 2010, Sub-investigator[BIBW1200.75]
- A phase Ⅲ clinical trial comparing Trastuzumab given concurrently with Radiation Therapy
and Radiation Therapy alone for women with HER-2 positive Ductal Carcinoma In situ resected by
Lumpectomy, sponsored by NSABP, 2010, Sub-investigator[NSABP B-43]
-A randomized, 3 arm, multicenter, phase III studyto evaluate the efficacy and the safety of T-DM1
combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for
pertuzumab), versus the combination of trastuzumab plus taxane, sponsored by Roche, 2010,
Sub-investigator [Marianne]
-A multicenter, multinational phase II study to assess the clinical safety and feasibility of T-DM1
sequentially with anthracycline-based chemotherapy, as adjuvant or neoadjuvant therapy for
patients with early stage HER2-positive breast cancer, sponsored by Roche, 2010, Sub-investigator
[TDM4874g][BO22857]
- A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus
Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients with HER2-Negative,
Unresectable, Locally-Recurrent or Metastatic Breast Cancer, sponsored by ICON, 2010, Principal
investigator [TRIO-012 study]
-A phase 2, randomised, double-blind, placebo-controlled,multi-centre study to assess the efficacy
and safety of AZD8931 in combination with Anastrozole,compared to anastrozole alone, in
post-menopausal women with hormone receptor-positive, endocrine therapy-naïve,
locally-advanced or metastatic breast cancer, sponsored by AstraZeneca, Principal investigator,
2010 [MINT]
- A randomized double-blind placebo-controlled tiral of neratinib (HKI-272) after trastuzumab in
women with early-stage HER-2/neu overexpressed/amplified breast cancer, sponsored by Wyeth,
2009, Sub-investigator
- A phase III, randomized, open-label study to compare pharmocokinetics, efficacy and safety of
subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with
HER2 positive early breast cancer (EBC), sponsored by Roche, 2009, Sub- investigator [HannaH]
- A phase 1/2, open-label study of neratinib (HKI-272) in combination with capecitabine in subjects
with solid tumors and erbB-2 positive metastatic or locally advanced breast cancer, sponsored by
Wyeth, 2009, sub-investigator [3144A1-2206-WW]
- A randomized, multicenter, phase III open-label study of the efficacy and safety of
trastuzumab-MCC-DM1 vs. capecitabine + lapatinib in patients with HER2-positive locally
advanced or metastatic breast cancer who have received prior tratuzumab-based therapy,
sponsored by Roche, 2009, Sub-investigator [EMILIA]
- A double-blind, Randomised, Parallel Phase I/IIb study to Evaluate Initial Safety and Efficacy,
Comparative Pharmacokinetics and Immunogenicity for CT-P6 and Herceptin in Metastatic breast
cancer, sponsored by Cell trion, 2009, Sub-investigator [Compare study]
- A randomized phase III, double-blind, placebo-controlled multicenter trial of everolimus in
combination with trastuzumab and paclitaxel, as first line therapy in women with HER2 positive
locally advanced or metastatic breast cancer, sponsored by Norvatis, 2009, Sub-investigator
[BOLERO-1: Breast cancer trials of OraL EveROlimus]
- A phase III randomized study of capecitabine as adjuvant chemotherapy versus observation in
breast cancer with pathologic residual tumors after preoperative chemotherapy, sponsored by
JBCRG, KBCSG, KCSG, 2009, Sub-investigator [CREATE-X: Capecitabine for Residual cancer as
Adjuvant ThErapy – X]

-4-